CGH
ALNY icon

Crossmark Global Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Crossmark Global Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389K Sell
1,291
-2
-0.2% -$603 0.01% 968
2026
Q1 		$428K Buy
1,293
+12
+0.9% +$4.08K 0.01% 886
2025
Q4 		$509K Buy
1,281
+57
+5% +$25.2K 0.01% 830
2025
Q3 		$558K Buy
1,224
+180
+17% +$73.3K 0.01% 848
2025
Q2 		$340K Buy
1,044
+26
+3% +$7.19K 0.01% 1043
2025
Q1 		$275K Buy
+1,018
New +$262K ﹤0.01% 1127
2024
Q4 		– Sell
-914
Closed -$251K – 1250
2024
Q3 		$251K Sell
914
-4
-0.4% -$1.04K ﹤0.01% 1149
2024
Q2 		$223K Buy
+918
New +$145K ﹤0.01% 1194
2024
Q1 		– Sell
-1,066
Closed -$204K – 1326
2023
Q4 		$204K Buy
+1,066
New +$182K ﹤0.01% 1246
2023
Q3 		– Sell
-1,062
Closed -$211K – 1261
2023
Q2 		$211K Sell
1,062
-72
-6% -$14.3K ﹤0.01% 1233
2023
Q1 		$227K Buy
1,134
+107
+10% +$22.5K 0.01% 1170
2022
Q4 		$244K Sell
1,027
-67
-6% -$14.3K 0.01% 1101
2022
Q3 		$219K Buy
+1,094
New +$209K 0.01% 1135
2018
Q3 		– Sell
-2,059
Closed -$203K – 1591
2018
Q2 		$203K Sell
2,059
-310
-13% -$30.7K 0.01% 1531
2018
Q1 		$282K Sell
2,369
-659
-22% -$85K 0.01% 1317
2017
Q4 		$385K Buy
3,028
+59
+2% +$7.41K 0.01% 1191
2017
Q3 		$349K Buy
+2,969
New +$253K 0.01% 1208
2016
Q3 		$349K Buy
+2,969
New +$209K 0.01% 1208

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crossmark Global Holdings's ALNY Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.15% in Q2 2026, selling an estimated $603 and leaving 1,291 shares worth $389K. The position accounts for 0.01% of the portfolio, ranked #968.

Crossmark Global Holdings first reported a position in ALNY in Q3 2016 and has held it in 18 quarters since. The position peaked at $558K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Crossmark Global Holdings held 1,291 shares of Alnylam Pharmaceuticals worth $389K as of Q2 2026.
  • Crossmark Global Holdings sold 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #968 holding.
  • Crossmark Global Holdings first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 18 quarters since.
  • Crossmark Global Holdings's Alnylam Pharmaceuticals position peaked at $558K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.